Table of contents
28 September 2020
Interferon Type I Regulates Inflammasome Activation and High Mobility Group Box 1 Translocation in Hepatocytes During Ehrlichia‐Induced Acute Liver Injury
Muhamuda Kader, Abdeljabar El Andaloussi, Jennie Vorhaour, Kenichi Tamama, Natalia Nieto, Melanie J. Scott, Nahed Ismail – 27 September 2020 – Inflammasomes are an important innate immune host defense against intracellular microbial infection. Activation of inflammasomes by microbial or host ligands results in cleavage of caspase‐1 (canonical pathway) or caspase‐11 (noncanonical pathway), release of interleukin (IL)‐1β, IL‐18, high mobility group box 1 (HMGB1), and inflammatory cell death known as pyroptosis.
Recipient Hepatic Vein as an Autologous Vascular Graft for Hepatic Vein Reconstruction in Living Donor Liver Transplantation
Yutaro Kato, Atsushi Sugioka, Yoshinao Tanahashi, Masayuki Kojima, Sanae Nakajima, Akira Yasuda, Junichi Yoshikawa, Toshihiro Yasui, Tatsuya Suzuki, Ichiro Uyama – 26 September 2020
Assessment of Adenosine Triphosphatase Phospholipid Transporting 8B1 (ATP8B1) Function in Patients With Cholestasis With ATP8B1 Deficiency by Using Peripheral Blood Monocyte‐Derived Macrophages
Ayumu Mizutani, Yusuke Sabu, Sotaro Naoi, Shogo Ito, Satoshi Nakano, Kei Minowa, Tatsuki Mizuochi, Koichi Ito, Daiki Abukawa, Shunsaku Kaji, Mika Sasaki, Koji Muroya, Yoshihiro Azuma, Satoshi Watanabe, Yuki Oya, Yukihiro Inomata, Akinari Fukuda, Mureo Kasahara, Ayano Inui, Hajime Takikawa, Hiroyuki Kusuhara, Kazuhiko Bessho, Mitsuyoshi Suzuki, Takao Togawa, Hisamitsu Hayashi – 26 September 2020 – Adenosine triphosphatase phospholipid transporting 8B1 (ATP8B1) deficiency, an ultrarare autosomal recessive liver disease, includes severe and mild clinical forms, referred to as progressive famil
Oligonucleotide‐Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases
Naim Alkhouri, G. Kesava Reddy, Eric Lawitz – 26 September 2020
State Medicaid Restrictions for Direct‐Acting Antiviral Therapy Do Not Impact Posttransplant Outcomes of Recipients of Hepatitis C Virus–Viremic Livers
Manasa Narasimman, David S. Goldberg – 26 September 2020
DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma
Lorenzo Nevi, Sabina Di Matteo, Guido Carpino, Ilaria Grazia Zizzari, Samira Safarikia, Valeria Ambrosino, Daniele Costantini, Diletta Overi, Antonella Giancotti, Marco Monti, Daniela Bosco, Valerio De Peppo, Andrea Oddi, Agostino Maria De Rose, Fabio Melandro, Maria Consiglia Bragazzi, Jessica Faccioli, Sara Massironi, Gian Luca Grazi, Pierluigi Benedetti Panici, Paquale Bartomeo Berloco, Felice Giuliante, Vincenzo Cardinale, Pietro Invernizzi, Giuseppina Caretti, Eugenio Gaudio, Domenico Alvaro – 25 September 2020
Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis
John E. Eaton, Christopher L. Welle, Zeinab Bakhshi, Shannon P. Sheedy, Ilkay S. Idilman, Gregory J. Gores, Charles B. Rosen, Julie K. Heimbach, Timucin Taner, Denise M. Harnois, Keith D. Lindor, Nicholas F. LaRusso, Andrea A. Gossard, Konstantinos N. Lazaridis, Sudhakar K. Venkatesh – 25 September 2020
Advance Care Planning: A Convincing Argument to Make It Part of Liver Transplant Evaluation
Manisha Verma, Tamar Taddei, Michael Volk, Victor Navarro – 25 September 2020
ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver‐Related Cirrhosis
Luis Calzadilla‐Bertot, Eduardo Vilar‐Gomez, Vincent Wai‐Sun Wong, Manuel Romero‐Gomez, Rocio Aller‐de la Fuente, Grace Lai‐Hung Wong, Marlen Castellanos, Mohammed Eslam, Archita P. Desai, Gary P. Jeffrey, Jacob George, Naga Chalasani, Leon A. Adams – 25 September 2020